Plain-English translation of NCT07216248 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether relugolix combined with another hormone-blocking medication can work effectively when given intermittently (on-and-off) rather than continuously in men with advanced prostate cancer. The study first gives all participants continuous treatment for 6–12 months. If your PSA (a prostate cancer marker in the blood) drops to very low levels, you may then be randomly assigned to either keep taking the medication continuously or switch to an on-and-off schedule to see if both approaches work equally well.
Currently, men with advanced prostate cancer take hormone-blocking medications continuously, which can cause side effects and affect quality of life. Researchers want to know if this medication can work just as well when taken intermittently, potentially reducing side effects while keeping the cancer under control.
You likely qualify if…
You likely don't qualify if…
You will start by taking the medication continuously (every day) for 6–12 months while your doctors monitor your PSA levels and overall health. If your PSA drops to very low levels and you meet other study requirements, you'll be randomly assigned to either continue daily medication or switch to an on-and-off schedule. Throughout the trial, you'll use a study app on your smartphone to help track your health and communicate with the research team.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States